doi:10.3969/j.issn.1673-8640.2016.03.020

Abstract

CLC Number:

R446.1

Figures/Tables 2

References 12

1	ROSENFELD H,ORNOY A,SHECHTMAN S,et al.Pregnancy outcome,thyroid dysfunction and fetal goitre after in utero exposure to propylthiouracil:a controlled cohort study[J].Br J Clin Pharmacol,2009,68(4):609-617.
2	顾金萍,宋梦帆,范建霞. 妊娠期甲状腺功能减退对妊娠结局和子代的影响[J].中华围产医学杂志,2011,14(6):374-378.
3	中华医学会内分泌学分会,中华医学会围产医学分会.妊娠和产后甲状腺疾病诊治指南[J]. 中华内分泌代谢杂志,2012,28(5):354-371.
4	叶任高,陆再英. 内科学[M]. 6版.北京:人民卫生出版社,2005:729-737.
5	柯文才,顾芸霞.不同妊娠期孕妇甲状腺激素水平的研究分析[J]. 检验医学,2015,30(3):224-226.
6	贾慧思,盖铭英.妊娠合并甲状腺功能减退[J]. 实用妇科杂志,2006,22(10):580-581.
7	LI Y, SHAN Z, TENG W, et al.Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25-30 months[J]. Clin Endocrinol(Oxf), 2010, 72(6):825-829.
8	薛海波,李元宾,滕卫平,等.妊娠早期母亲亚临床甲状腺功能减退症对其后代脑发育影响的前瞻性研究[J]. 中华内分泌代谢杂志,2010,26(11):916-920.
9	刘迪杰,单忠艳,滕卫平,等.妊娠期亚临床甲减大鼠对子代学习记忆能力及脑发育相关基因表达的影响[J].中华内分泌代谢杂志,2010,26(11):936-941.
10	董丽,孙丽芳.甲状腺自身抗体和促甲状腺素预测流产的价值[J].中国妇产科临床杂志,2011,12(3):191-193.
11	单忠艳,滕卫平.倡导妊娠期甲状腺疾病筛查,保护后代智力发育[J]. 中华内分泌代谢杂志,2010,26(11):913-915.
12	DEMERS LM,SPENCER CA.Laboratory medicine practice guidelines: Laboratory support for the diagnosis and monitoring of thyroid disease[J]. Clin Endocrinol(Oxf),2003,58(2):138-140.

组别	例数	临床甲减（例）	亚临床甲减（例）	临床甲亢（例）	亚临床甲亢（例）	甲状腺功能异常
组别	例数	临床甲减（例）	亚临床甲减（例）	临床甲亢（例）	亚临床甲亢（例）	合计（例）	异常率（%）
妊娠早期组	269	0	16	2	0	18	6.69
妊娠中期组	562	2	40	0	2	44	7.83
妊娠晚期组	716	3	54	2	1	60	8.38
合计	1 547	5	110	4	3	122	7.89

组别	例数	临床甲减（例）	亚临床甲减（例）	临床甲亢（例）	亚临床甲亢（例）	甲状腺功能异常
组别	例数	临床甲减（例）	亚临床甲减（例）	临床甲亢（例）	亚临床甲亢（例）	合计（例）	异常率（%）
妊娠早期组	269	0	16	2	0	18	6.69
妊娠中期组	562	2	40	0	2	44	7.83
妊娠晚期组	716	3	54	2	1	60	8.38
合计	1 547	5	110	4	3	122	7.89

组别	例数	FT4（pmol/L）	TSH（mIU/L）
妊娠早期组	269	15.99±2.16^*	1.29±0.41^*
妊娠中期组	562	14.11±2.24^*#	1.98±0.39^*#
妊娠晚期组	716	12.14±2.10^*#▲	2.36±0.32^*#▲
正常对照组	60	16.87±3.16	3.46±0.88

组别	例数	FT4（pmol/L）	TSH（mIU/L）
妊娠早期组	269	15.99±2.16^*	1.29±0.41^*
妊娠中期组	562	14.11±2.24^*#	1.98±0.39^*#
妊娠晚期组	716	12.14±2.10^*#▲	2.36±0.32^*#▲
正常对照组	60	16.87±3.16	3.46±0.88

[1]	GAO Zikang, CHEN Jing. Construction of a nomogram prediction model for the prognosis of patients with depressive disorder based on the characteristics of peripheral blood lymphocyte subsets [J]. Laboratory Medicine, 2025, 40(12): 1146-1152.
[2]	WANG Tian, ZHANG Yun, BAI Yi, ZHAI Weibin, ZHAO Hai. Roles of PIV，SII and NPAR in the diagnosis of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites [J]. Laboratory Medicine, 2025, 40(12): 1153-1158.
[3]	HUANG Ting, XU Yan, SHI Qingxing, PENG Ying. Roles of miR-944 and MARCH7 mRNA in prognosis assessment of non-small cell lung cancer patients [J]. Laboratory Medicine, 2025, 40(12): 1159-1164.
[4]	LI Minghong, MIN Cuili, GUO Qingbo, MA Lujuan. Predictive roles of serum 25（OH）D and SAA for the response to immunosuppressive therapy in autoimmune hepatitis [J]. Laboratory Medicine, 2025, 40(12): 1165-1170.
[5]	ZHEN Di, JIA Bin, MENG Xianyi. Roles of serum sPD-1 and sTWEAK levels in patients with ulcerative colitis in disease monitoring and prognosis assessment [J]. Laboratory Medicine, 2025, 40(12): 1171-1176.
[6]	ZHAO Yilin, XU Yan, YIN Hui. Roles of serum miR-145-5p，miR-200C-3p and miR-1290 in prognosis assessment of patients with papillary thyroid carcinoma [J]. Laboratory Medicine, 2025, 40(12): 1177-1182.
[7]	LI Song, XIANG Xu. Risk factors for poor prognosis in elderly patients with severe fever and thrombocytopenia syndrome and their clinical significance [J]. Laboratory Medicine, 2025, 40(12): 1183-1189.
[8]	CHANG Nan, WEI Yali, LU Qifeng, LI Tian, HOU Tingting, LI Yuan, ZHU Mengyu, SHEN Yajuan. A machine learning early warning model for acute promyelocytic leukemia based on blood cell analyzer parameters [J]. Laboratory Medicine, 2025, 40(12): 1190-1196.
[9]	. [J]. Laboratory Medicine, 2025, 40(12): 1197-1202.
[10]	. [J]. Laboratory Medicine, 2025, 40(12): 1216-1221.
[11]	. [J]. Laboratory Medicine, 2025, 40(12): 1222-1226.
[12]	BAO Wen. Application and prospect of microsatellite instability determination in tumor diagnosis and treatment [J]. Laboratory Medicine, 2025, 40(12): 1227-1231.
[13]	XIONG Ying, GUO Wei. From generic to personalized：the evolution and frontiers of indirect methods for establishing reference interval [J]. Laboratory Medicine, 2025, 40(11): 1035-1041.
[14]	CHEN Yanqin, FAN Lina, YANG Dagan. Six indirect method algorithms for establishing the reference range of serum cystatin C for adults in Hangzhou and consistency analysis [J]. Laboratory Medicine, 2025, 40(11): 1047-1052.
[15]	LIU Chunyan, NIU Shumin, DENG Zhaohui, LIANG Mengjie, ZHANG Xin. Establishing the reference ranges for AFP，CEA，CA72-4 and CA19-9 in Urumqi region by indirect method [J]. Laboratory Medicine, 2025, 40(11): 1053-1058.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 12

Related Articles 15

Recommended Articles

Metrics